SCHEMBL16210266

SCHEMBL16210266

CC(C)CNC(=O)C1CCN(C2CCCN(C(=O)OC(C)(C)C)CC2)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM1 P11229 2/20 0.50
HPGD P15428 1/20 0.49
PTPN2 P17706 1/20 0.44
PTPN1 P18031 1/20 0.44
PTPN6 P29350 1/20 0.44
ABL1 P00519 1/20 0.43
RIN1 Q13671 1/20 0.43
KMT2A Q03164 3/20 0.43
ALDH1A1 P00352 2/20 0.43
MEN1 O00255 1/20 0.43
MAPT P10636 1/20 0.43
RECQL P46063 1/20 0.42
EPHX1 P07099 1/20 0.42
GPR119 Q8TDV5 1/20 0.41
STS P08842 1/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
EPHX2 P34913 1/20 0.41
LMNA P02545 1/20 0.40
MMP3 P08254 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14978809 1.00 CHRM1 (0.50) CHRM1HPGDPTPN2PTPN1PTPN6
SCHEMBL1580316 0.88 HPGD (0.54) HPGDPTPN2PTPN1PTPN6KMT2A
SCHEMBL14978767 0.88 CHRM1 (0.65) CHRM1HPGDALDH1A1MAPTLMNA
SCHEMBL14964864 0.88 CHRM1 (0.65) CHRM1HPGDALDH1A1MAPTLMNA
SCHEMBL14978775 0.88 CHRM1 (0.65) CHRM1HPGDALDH1A1MAPTLMNA
SCHEMBL14978777 0.85 CHRM1 (0.52) CHRM1KMT2AALDH1A1RAB9ALMNA
SCHEMBL14964899 0.85 KMT2A (0.47) CHRM1KMT2AALDH1A1MEN1RAB9A
SCHEMBL14978772 0.85 CHRM1 (0.56) CHRM1HPGDKMT2AALDH1A1LMNA
SCHEMBL14964766 0.84 CHRM1 (0.53) CHRM1KMT2AALDH1A1RAB9ALMNA
SCHEMBL14978902 0.84 CHRM1 (0.53) CHRM1KMT2AALDH1A1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11793817-B2 Muscarinic M1 receptor agonists HEPTARES THERAPEUTICS LIMITED (GB) 2023-10-24 US disclosed
US-20210353637-A1 MUSCARINIC M1 RECEPTOR AGONISTS NXERA PHARMA UK LIMITED (GB) 2021-11-18 US disclosed
US-10973832-B2 Muscarinic M1 receptor agonists HEPTARES THERAPEUTICS LIMITED (GB) 2021-04-13 US disclosed
US-20200253982-A1 MUSCARINIC M1 RECEPTOR AGONISTS NXERA PHARMA UK LIMITED (GB) 2020-08-13 US disclosed
US-10413553-B2 Muscarinic M1 receptor agonists HEPTARES THERAPEUTICS LIMITED (GB) 2019-09-17 US disclosed
US-20180153900-A1 MUSCARINIC M1 RECEPTOR AGONISTS NXERA PHARMA UK LIMITED (GB) 2018-06-07 US disclosed
US-9907805-B2 Muscarinic M1 receptor agonists HEPTARES THERAPEUTICS LIMITED (GB) 2018-03-06 US disclosed
US-20170157139-A1 MUSCARINIC M1 RECEPTOR AGONISTS NXERA PHARMA UK LIMITED (GB) 2017-06-08 US disclosed
US-9573929-B2 Muscarinic M1 receptor agonists HEPTARES THERAPEUTICS LIMITED (GB) 2017-02-21 US disclosed
EP-2780015-B1 MUSCARINIC M1 RECEPTOR AGONISTS HEPTARES THERAPEUTICS LTD (GB) 2017-01-04 EP disclosed
US-20160068508-A1 Muscarinic M1 Receptor Agonists NXERA PHARMA UK LIMITED (GB) 2016-03-10 US disclosed
US-9187451-B2 Muscarinic M1 receptor agonists HEPTARES THERAPEUTICS LIMITED (GB) 2015-11-17 US disclosed
US-20140329803-A1 MUSCARINIC M1 RECEPTOR AGONISTS NXERA PHARMA UK LIMITED (GB) 2014-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140329803-A1 MUSCARINIC M1 RECEPTOR AGONISTS CHRM1, CHRM2, CHRM3 CHRM1 1/4885HPGD 2584/4885PTPN2 1637/4885
US-20180153900-A1 MUSCARINIC M1 RECEPTOR AGONISTS CHRM1, CHRM2, CHRM3 CHRM1 1/4885HPGD 2584/4885PTPN2 1637/4885
US-20160068508-A1 Muscarinic M1 Receptor Agonists CHRM1, CHRM2, CHRM3 CHRM1 1/4885HPGD 2584/4885PTPN2 1637/4885
US-20200253982-A1 MUSCARINIC M1 RECEPTOR AGONISTS CHRM1, CHRM2, CHRM3 CHRM1 1/4885HPGD 2584/4885PTPN2 1637/4885
US-20210353637-A1 MUSCARINIC M1 RECEPTOR AGONISTS CHRM1, CHRM2, CHRM3 CHRM1 1/4885HPGD 2584/4885PTPN2 1637/4885
US-20170157139-A1 MUSCARINIC M1 RECEPTOR AGONISTS CHRM1, CHRM2, CHRM3 CHRM1 1/4885HPGD 2584/4885PTPN2 1637/4885
US-10973832-B2 Muscarinic M1 receptor agonists CHRM1, CHRM2, CHRM3 CHRM1 1/4885HPGD 2584/4885PTPN2 1637/4885
US-10413553-B2 Muscarinic M1 receptor agonists CHRM1, CHRM2, CHRM3 CHRM1 1/4885HPGD 2584/4885PTPN2 1637/4885
US-11793817-B2 Muscarinic M1 receptor agonists CHRM1, CHRM2, CHRM3 CHRM1 1/4885HPGD 2584/4885PTPN2 1637/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.